

Pulmonary hypertension Bologna 2019

Work in Progress for the
7th World Symposium
on Pulmonary Hypertension

ROYAL HOTEL CARLTON • *Bologna, Italy*

November 29 • 30, 2019

With the endorsement of



World Symposium on Pulmonary
Hypertension Association



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI MEDICINA SPECIALISTICA,
DIAGNOSTICA E SPERIMENTALE

POLICLINICO DI
SANT'ORSOLA

SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Operativa - Università di Bologna

PHAEUROPE
European pulmonary hypertension association

AIPI
ASSOCIAZIONE IPERTENSIONE
PULMONARE ITALIANA ONLUS

Friday, November 29

13:30 – 14:00

Introduction and presentation
of the meeting objectives

N. Galiè

14:00 – 16:00

EVOLUTIONS ON DEFINITIONS AND CLASSIFICATION

Chairs: N. Galiè, G. Simonneau

Is it already time to adjust the 5-group
pulmonary hypertension clinical
classification?

G. Simonneau

Interactions between clinical and
pathological classification: any practical
insights?

P. Dorfmueller

New haemodynamic definition and its
practical application on each clinical group

N. Galiè

Pulmonary hypertension on exercise:
current definitions, possible clinical
applications, limitations, and perspectives

G. Kovacs

16:00 – 16:30

Coffee break

16:30 – 18:30

PULMONARY HYPERTENSION DUE TO HEART DISEASE OR LUNG DISEASE: TWO GIANTS LOOKING FOR DIRECTIONS

Chairs: S.P. Gaine, J.L. Vachiéry

Pulmonary hypertension due to left heart
disease: diagnostic pitfall, epidemiology,
and clinical consequences

S. Gibbs

Pulmonary hypertension due to left heart
disease: current evidence based treatment
and future lines of research

J.L. Vachiéry

Pulmonary hypertension due to lung
disease: diagnosis, epidemiology and
clinical consequences

S.P. Gaine

Pulmonary hypertension due to lung
disease: current evidence based treatment
and future lines of research

I. Blanco

18:30 – 18:45

Summary of the day

N. Galiè

Pulmonary
hypertension
Bologna 2019

Saturday, November 30

09:00 – 10:30

CURRENT STATE OF THE ART OF PULMONARY ARTERIAL HYPERTENSION TREATMENT

Chairs: I. Blanco, O. Sitbon

Risk stratification and treatment algorithm

A. Manes

Treatment of intermediate-risk patients: different possible strategies

F. Dardi

Phase 2 and phase 3 clinical trials structure for new candidate drugs for pulmonary arterial hypertension

O. Sitbon

10:30 – 10:45

Coffee break

10:45 – 12:00

EVOLVING TREATMENT STRATEGIES FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION/DISEASE

Chairs: D.P. Jenkins, D. Pacini

Balloon pulmonary angioplasty in CTEPH

M. Palazzini

Pulmonary endarterectomy

D.P. Jenkins

Pulmonary endarterectomy: the Bologna experience

S. Martin-Suarez

12:00 – 13:45

THE CLINICAL CASES

Chairs: A. Manes, M. Palazzini

Case # 1 – A PAH low-risk case

E. Zuffa

Case # 2 – A PAH intermediate-risk case

A. De Lorenzis

Case # 3 – A PAH high-risk case

I. Magnani

Case # 4 – CTEPH decision making

F. Pasca

Case # 5 – PH due to congenital heart disease

G. Giannakoulas

Case # 6 – PH due to connective tissue disease

D. Guarino

13:45 – 13:50

Summary of the day and conclusions

N. Galie`

13:50 – 14:45

Lunch

Isabel Blanco

*Pulmonary Hypertension Unit
Respiratory Medicine Department
Hospital Clinic of Barcelona
Barcelona, Spain*

Fabio Dardi

*Department of Experimental, Diagnostic and Specialty
Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

Alessandro De Lorenzis

*Department of Experimental, Diagnostic and Specialty
Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

Peter Dorfmueller

*Department of Pathology and
German Centre for Lung Research (DZL)
University Hospital Giessen and Marburg
Giessen, Germany*

Sean Patrick Gaine

*National Pulmonary Hypertension Unit
Mater Misericordiae University Hospital
Dublin, Ireland*

Nazzareno Galiè

*Department of Experimental, Diagnostic and Specialty
Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

Georgios Giannakoulas

*Adult Congenital Heart Disease and Pulmonary
Hypertension Clinic- Ahepa University Hospital
Thessaloniki, Greece*

Simon Gibbs

*Department of Cardiology
Imperial College London and Hammersmith Hospital
London, United Kingdom*

Daniele Guarino

*Department of Experimental, Diagnostic and Specialty
Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

David P. Jenkins

*Department of Cardiothoracic Surgery
Royal Papworth Hospital
Cambridge, United Kingdom*

Gabor Kovacs

*Division of Pneumology
Department of Internal Medicine
Medical University of Graz
Graz, Austria*

Ilenia Magnani

*Department of Experimental, Diagnostic and Specialty
Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

Alessandra Manes

*Department of Experimental, Diagnostic and Specialty
Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

Sofía Martin Suarez

*Department of Experimental, Diagnostic and Specialty
Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

Davide Pacini

*Department of Experimental,
Diagnostic and Specialty Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

Massimiliano Palazzini

*Department of Experimental, Diagnostic and Specialty
Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

Filippo Pasca

*Department of Experimental, Diagnostic and Specialty
Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

Gérald Simonneau

*Department of Pneumology and ICU
National Reference Center for Pulmonary Hypertension
South Paris University, Bicêtre Hospital
Le Kremlin Bicêtre, France*

Olivier Sitbon

*Department of Pneumology and ICU
National Reference Center for Pulmonary Hypertension
South Paris University, Bicêtre Hospital
Le Kremlin Bicêtre, France*

Jean Luc Vachiéry

*University Clinic of Brussels, Erasme Hospital
Brussels, Belgium*

Elisa Zuffa

*Department of Experimental,
Diagnostic and Specialty Medicine - DIMES
Alma Mater Studiorum University of Bologna
Bologna, Italy*

Congress Venue

ROYAL HOTEL CARLTON

Via Montebello 8 - BOLOGNA, ITALY

Italian Cme Credits

Provider Italian CME Credits:

I&C srl PROVIDER: 5387

ID CME ITALIAN CREDITS: 5387 - 275226

CME CREDITS: **n. 6,3**

DURATION OF THE SCIENTIFIC ACTIVITY: 9 hrs

I&C srl is responsible for the content, the quality and the ethical honesty of the CME activity.

The meeting will be accredited for physicians, disciplines: Internal Medicine, Cardiology, Diseases Respiratory System, Rheumatology, Cardio Surgery, Thoracic Surgery, Vascular Surgery, General Surgery, Anesthesia and Resuscitation, General Medicine, Allergology and Clinical Immunology, Sport Medicine.

The physicians belonging to other disciplines will not get the credits.

The attendance to the meeting is partially on sponsor companies invitation.

METHODOLOGY

Residential

COURSE OBJECTIVES

Clinical, Diagnostic, Therapy, Treatment Path

LEARNING TEST

In order to obtain CME credits, it is mandatory for participants to attend 90% of the course both days and to complete CME procedures online: CME test multiple choice questions, minimum score 75%, learners' feedback form and educational needs form. Instructions will be provided on site.



Eaccme Credits

EACCME® Accreditation of event reference

#LEE19-01475

The PULMONARY HYPERTENSION BOLOGNA 2019: WORK IN PROGRESS FOR THE 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION, Bologna, Italy, 29/11/2019-30/11/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 8 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:

29.11.2019 - 4.00

30.11.2019 - 4.00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

European CME credits have been requested for the following disciplines: Internal Medicine, Cardiology, Diseases Respiratory System, Rheumatology, Cardio Surgery, Thoracic Surgery, Vascular Surgery, General Surgery, Anesthesia and Resuscitation, General Medicine, Allergology and Clinical Immunology, Sport Medicine.

Scientific Secretariat

Prof. Nazzareno Galie`

Director of the Course

Dr. Alessandra Manes

Dr. Massimiliano Palazzini

Center of Diagnosis and Therapy of Pulmonary Arterial Hypertension

Department of Experimental, Diagnostic and Specialty Medicine – DIMES

Alma Mater Studiorum

University of Bologna

Via Massarenti, 9 - 40138 Bologna

Tel. +39 051 6364008

Fax +39 051 344859

e-mail: nazzareno.galie@unibo.it

Organizing Secretariat



I&C srl

Via A. Costa 202/6

40134 Bologna (Italy)

Tel: +39 (0)51 6144004

Fax: +39 (0)51 6142772

stefania.parolari@iec-srl.it; giulia.delia@iec-srl.it

www.iec-srl.it

With the non conditioning sponsorship of



ACTELION

A JANSSEN PHARMACEUTICAL COMPANY

OF *Johnson & Johnson*



Dompé

ferrero